A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Status:
Completed

Trial end date:
2017-04-24

Target enrollment:

Participant gender:

An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease

Phase 2

Novartis Pharmaceuticals